Oral ulcers, a little known adverse effect of alendronate: Review of the literature

Journal of Oral and Maxillofacial Surgery

Volumn 70, Issue 4, 2012, Pages 830-836

  Kharazmi, Mohammad ^a   Sjöqvist, Kerstin ^a   Warfvinge, Gunnar ^b  

^a CENTRAL HOSPITAL   (Sweden)

^b MALMÖ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MEDLINE; MOUTH CAVITY; MOUTH ULCER; REVIEW; TREATMENT DURATION; ULCER HEALING;

EID: 84859107748     PISSN: 02782391     EISSN: 15315053     Source Type: Journal    
DOI: 10.1016/j.joms.2011.03.046     Document Type: Article

References (38)

1. R.E. Marx Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic J Oral Maxillofac Surg 61 2003 1115
2. S.L. Ruggiero, B. Mehrotra, T.J. Rosenberg Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases J Oral Maxillofac Surg 62 2004 527
3. P.C. de Groen, D.F. Lubbe, L.J. Hirsch Esophagitis associated with the use of alendronate N Engl J Med 335 1996 1016
4. N. Demerjian, G. Bolla, A. Spreux Severe oral ulcerations induced by alendronate Clin Rheumatol 18 1999 349
5. M.A. Gonzalez-Moles, J.V. Bagan-Sebastian Alendronate-related oral mucosa ulcerations J Oral Pathol Med 29 2000 514
6. J. Schmutz, A. Barbaud, P. Tréchot Alendronate monosodique (Fosamax®) (Esophagites et ulcerations orales) Ann Dermatol Venereol 127 2000 1138
7. K. Krasagakis, S. Krger-Krasagakis, D. Ioannidou Chronic erosive and ulcerative oral lesions caused by incorrect administration of alendronate J Am Acad Dermatol 50 2004 651
8. J.L. Schmutz, A. Barbaud, P. Trechot Alendronate et ulcerations buccales: D'abord bien interroger le patient Ann Dermatol Venereol 132 2005 930
9. P. Rubegni, M. Fimiani Images in clinical medicine: Bisphosphonate- associated contact stomatitis N Engl J Med 355 2006 e25
10. N. Ponte-Fernndez, R. Estefania-Fresco, J.M. Aguirre-Urizar Bisphosphonates and oral pathology I General and preventive aspects Med Oral Patol Oral Cir Bucal 11 2006 E396
11. I. Jackson, N. Malden Lingual mucosal ulceration with mandibular sequestration Dent Update 34 2007 573
12. A. Dicko, A. Toulemonde, F. Hoareau Ulcérations buccales Ann Dermatol Venereol 134 2007 389
13. F. Cardona-Tortajada, E. Sainz-Gómez, J. Figuerido-Garmendia lcera oral crónica por ingestion de alendronato Aten Primaria 40 2008 430
14. N.S. Treister, P. Richardson, R. Schlossman, K. Miller, S.B. Woo Painful tongue ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws Oral Surg Oral Med Oral Pathol Oral Radiol Endod 105 2008 e1
15. P.J. Dhanrajani Lingual mucosal ulceration with mandibular sequestration Dent Update 34 2007 573
16. W. Aleid, A. Sidebottom Oral mucosal irritation with incorrect use of alendronate Br J Oral Maxillofac Surg 47 2009 170
17. M. Garca-Font, N. Curcó, C. Prat Mouth sores caused by alendronate Actas Dermosifiliogr 100 2009 77
18. M. Kharazmi, K. Sjöqvist, M. Rizk Oral ulcer associated with alendronate: A case report Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110 2010 e11
19. E.A. Dik, R.J. van Es, J.E. Bergsma A toxic reaction of the oral mucosa to alendronate (Fosamax) Ned Tijdschr Tandheelkd 117 2010 387
20. A. Spreux, M. Amples, G. Bolla Ulceration muqueuses topographiquement atypiques avec l'alendronate Thérapie 53 1998 182
21. A.A. Reszka, J. Halasy-Nagy, G.A. Rodan Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation Mol Pharmacol 59 2001 193
22. M.J. Rogers New insights into the molecular mechanisms of action of bisphosphonates Curr Pharm Des 9 2003 2643
23. S. Suri, J. Mnkknen, M. Taskinen Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-induced gastrointestinal toxicity Bone 29 2001 336
24. R. Landesberg, M. Cozin, S. Cremers Inhibition of oral mucosal cell wound healing by bisphosphonates J Oral Maxillofac Surg 66 2008 839
25. V.F.P. Correia, C.L. Caldeira, M.M. Marques Cytotoxicity of sodium alendronate on cultured human periodontal ligament fibroblasts Dent Traumatol 22 2006 312
26. J. Wood, K. Bonjean, S. Ruetz Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid J Pharmacol Exp Ther 302 2002 1055
27. D. Santini, B. Vincenzi, G. Dicuonzo Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients Clin Cancer Res 9 2003 2893
28. G. Yin, Y. Bai, E. Luo Angiogenic suppression of osteoclasts may play a role in developing bisphosphonate-related osteonecrosis of the jaw Med Hypotheses 76 2011 347
29. J.L. Wallace, M. Dicay, W. McKnight, S. Bastaki, M.A. Blank N-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation Aliment Pharmacol Ther 13 1999 1675
30. S.N. Elliott, W. McKnight, N.M. Davies, W.K. MacNaughton, J.L. Wallace Alendronate induces gastric injury and delays ulcer healing in rodents Life Sci 62 1998 77
31. T. Schnitzer, H.G. Bone, G. Crepaldi Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis: Alendronate Once-Weekly Study Group Aging (Milano) 12 2000 1
32. C.G. Engeland, J.A. Bosch, J.T. Cacioppo Mucosal wound healing: The roles of age and sex Arch Surg 141 2006 1193
33. Adverse Drug Reactions Committee (ADRAC) A gut feeling for alendronate Aust Adv Drug React Bull 18 1999 11
34. F.L. Lanza, R.H. Hunt, A.B. Thomson Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women Gastroenterology 119 2000 631
35. K. Kanatsu, E. Aihara, M. Okayama, S. Kato, K. Takeuchi Mucosal irritative and healing impairment action of risedronate in rat stomachs: Comparison with alendronate J Gastroenterol Hepatol 19 2004 512
36. R.E. Marx Clinical concerns of alendronate use J Oral Maxillofac Surg 66 2008 1322
37. D.M. Black, P.D. Delmas, R. Eastell Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 2007 1809
38. V. Dao, R.A. Kraut Bisphosphonate use and health history questionnaire N Y State Dent J 74 2008 20